645400-44-8 Usage
Uses
Used in Pharmaceutical Industry:
Carbamic acid, [(1S,3S)-3-aminocyclopentyl]-, 1,1-dimethylethyl ester (9CI) is used as a reactant in the synthesis of C-2 hydroxyethyl imidazopyrrolo pyridines. These compounds serve as JAK1 inhibitors, which are important in the development of drugs targeting the Janus kinase (JAK) family of enzymes. Inhibition of JAK1 can help regulate immune responses and has potential therapeutic applications in treating autoimmune diseases and inflammatory conditions.
Synthesis
A flask containing tert-butyl [(1S,3S)-3-aminocyclopentyl]carbamate (16.5 g, crude ~0.05 mol) and 1.7 g Pd-C (10% paste) in MeOH (300 mL) was exposed to a positive pressure of hydrogen gas (balloon) over weekend. The catalyst was filtered off and the mixture was concentrated to afford the title compound (9.5 g) as a thick colorless viscous oil. Tert-butyl [(1S,3S)-3-aminocyclopentyl]carbamate, Yield (9.5 g)
Check Digit Verification of cas no
The CAS Registry Mumber 645400-44-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,4,5,4,0 and 0 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 645400-44:
(8*6)+(7*4)+(6*5)+(5*4)+(4*0)+(3*0)+(2*4)+(1*4)=138
138 % 10 = 8
So 645400-44-8 is a valid CAS Registry Number.
645400-44-8Relevant academic research and scientific papers
4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS
-
, (2010/02/11)
Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.
THERAPEUTIC AGENTS I
-
Page/Page column 36, (2010/02/12)
Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.
MCHIR ANTAGONISTS
-
Page/Page column 25, (2008/06/13)
The present invention provides compounds of formula (I), wherein R1 represents a C1-4alkoxy group optionally substituted by one or more fluoro or a C1-4alkyl group optionally substituted by one or more fluoro; n represents
